More about

Drug-Eluting Stent

News
April 20, 2020
1 min read
Save

PRECOMBAT

PRECOMBAT

Long-term outcomes of PCI with a sirolimus-eluting stent vs. CABG for unprotected left main CAD.

News
February 24, 2020
2 min read
Save

BIOFLOW V: SES reduces event rates at 3 years vs. EES

BIOFLOW V: SES reduces event rates at 3 years vs. EES

Patients who underwent coronary revascularization with a bioresorbable polymer sirolimus-eluting stent had significantly lower rates of target vessel MI, late/very late stent thrombosis and clinically driven target lesion revascularization compared with those who underwent the procedure with a durable polymer everolimus-eluting stent, according to 3-year data from the BIOFLOW V trial presented at Cardiovascular Research Technologies.

News
January 31, 2020
2 min read
Save

Meta-analysis of paclitaxel-coated balloons in CLI ‘should have no meaningful impact’

Meta-analysis of paclitaxel-coated balloons in CLI ‘should have no meaningful impact’

A recent meta-analysis detecting a signal of harm at 1 year in patients with below-the-knee lesions treated with paclitaxel-coated balloons is flawed and should not impact clinical practice, a speaker said at the International Symposium on Endovascular Therapy.

News
January 09, 2020
2 min read
Save

PCI with ridaforolimus-eluting stent confers similar 2-year outcomes as ZES

PCI with ridaforolimus-eluting stent confers similar 2-year outcomes as ZES

Outcomes at 2 years were similar for patients who underwent PCI with a ridaforolimus-eluting stent compared with a zotarolimus-eluting stent, according to a pooled analysis of two randomized trials published in JACC: Cardiovascular Interventions.

News
December 01, 2019
1 min read
Save

Top stories from VIVA: Peripheral DES, drug-coated balloons and more

Top stories from VIVA: Peripheral DES, drug-coated balloons and more

Healio and Cardiology Today present meeting highlights from VIVA 19 in Las Vegas. Top stories included the latest from the IMPERIAL head-to-head comparison of two peripheral drug-eluting stents, a low-dose paclitaxel-coated balloon, new advances for patients with critical limb ischemia and more.

News
November 14, 2019
3 min read
Save

Bioresorbable scaffold effectively treats below-the-knee lesions

Bioresorbable scaffold effectively treats below-the-knee lesions

LAS VEGAS — A bioresorbable scaffold was shown to be safe and effective for treatment of below-the-knee lesions in two studies presented at VIVA 19.

News
November 07, 2019
2 min read
Save

Sirolimus-coated balloon benefit maintained at 2 years

Sirolimus-coated balloon benefit maintained at 2 years

LAS VEGAS — A sirolimus-coated balloon for treatment of peripheral artery disease was associated with positive outcomes at 2 years, according to new data from the SELUTION study presented at VIVA 19.

News
November 05, 2019
2 min read
Save

IMPERIAL: Peripheral DES similar in patency, different in TLR at 2 years

IMPERIAL: Peripheral DES similar in patency, different in TLR at 2 years

LAS VEGAS — A peripheral drug-eluting stent with a polymer coating conferred lower rates of target lesion revascularization compared with a peripheral DES without a polymer coating, according to 2-year results from the IMPERIAL trial.

News
November 05, 2019
3 min read
Save

Mortality not different at 5 years in patients treated with DES vs. controls

Mortality not different at 5 years in patients treated with DES vs. controls

LAS VEGAS — There were no significant differences in mortality at 5 years between patients with peripheral artery disease assigned a drug-eluting stent and those assigned a bare-metal stent or percutaneous transluminal angioplasty, according to new data presented at VIVA 19.

News
October 31, 2019
2 min read
Save

Ticagrelor monotherapy similar to DAPT regimen 2 years after stenting

Ticagrelor monotherapy similar to DAPT regimen 2 years after stenting

Confirming previously presented results, ticagrelor monotherapy after 1 month of dual antiplatelet therapy was similar to a standard DAPT regimen for the prevention of ischemic events without differences in bleeding following drug-eluting coronary stenting.

View more